To the Editor We read with interest the cohort study conducted by Tichelli and colleagues1 of patients who developed a second solid cancer (SSC) after a transplant. Hematopoietic stem cell transplant (HSCT) recipients have a considerable risk of developing secondary solid cancers 5 years or more after HSCT owing to factors such as myeloablative total-body irradiation, young age at HSCT, chronic graft-vs-host disease, and prolonged immunosuppressive treatment longer than 24 months.2,3 Therefore, Inamoto et al4 proposed guidelines to help clinicians provide screening and preventive care for secondary cancers among HSCT recipients.